Prostate cancer metastasis remains one of the greatest clinical challenges, significantly escalating mortality associated with this common malignancy. While previous research has extensively investigated genetic mutations and signaling pathways driving cancer spread, this study introduces a fresh perspective by linking metabolic regulation and epigenetic modifications to metastatic behavior. RBM14, traditionally recognized for its role in RNA metabolism, has now emerged as a critical mediator stabilizing HK2 mRNA, thereby sustaining elevated glycolytic activity. This metabolic reprogramming provides metastatic cancer cells with a rapid energy supply and biosynthetic precursors essential for invasion and survival in distant tissues.

The molecular architecture of this pathway reveals that RBM14 binds directly to HK2 mRNA, protecting it from degradation. Hexokinase 2 (HK2) is a key enzyme catalyzing the initial step of glycolysis by phosphorylating glucose to glucose-6-phosphate, effectively committing glucose to cellular energy metabolism. Enhanced HK2 expression driven by RBM14 ensures an abundant flux through glycolysis, a hallmark of aggressive cancer metabolism often termed the “Warburg effect”. However, the authors uniquely emphasize that this metabolic shift is not merely a consequence but an active driver of metastatic progression thanks to its downstream effects on chromatin modifications.

Intriguingly, the robust glycolytic activity fueled by RBM14-mediated HK2 stabilization leads to elevated intracellular lactate levels. Lactate, traditionally regarded as a metabolic byproduct, has recently been recognized for its signaling functions and involvement in epigenetic regulation. The study highlights H3K18 lactylation, a histone modification where lactate moieties are appended to lysine 18 on histone H3, as a direct epigenetic mark induced by this metabolic rewiring. This histone lactylation event significantly reprograms gene expression profiles to favor metastatic phenotypes, including enhanced motility, invasiveness, and resistance to apoptosis.

From a biochemical perspective, this research integrates the fields of RNA biology, metabolism, and epigenetics into a comprehensive framework explaining prostate cancer metastasis. The use of advanced RNA immunoprecipitation and next-generation sequencing analyses validated the binding affinity of RBM14 for HK2 transcripts and demonstrated the consequent augmentation in glycolytic gene networks. Furthermore, chromatin immunoprecipitation coupled with mass spectrometry provided compelling evidence for the presence and functional significance of H3K18 lactylation in tumor samples exhibiting high RBM14 expression.

In vitro and in vivo experiments further consolidated the conceptual model, where knockdown of RBM14 led to the destabilization of HK2 mRNA, a marked decrease in glycolysis rates, and subsequent reduction in H3K18 lactylation. This intervention translated into diminished metastatic potential in prostate cancer cell lines and mouse xenograft models, underscoring the therapeutic promise of targeting RBM14 or its downstream metabolic and epigenetic pathways. Notably, the study also explored small molecule inhibitors capable of disrupting the RBM14-HK2 interaction, revealing preliminary efficacy in curtailing metastatic spread.

This body of work not only highlights RBM14 as a molecular linchpin in prostate cancer metastasis but also challenges the traditional compartmentalization of metabolic and epigenetic regulation as independent axes of cancer biology. The interplay elucidated here points to a highly integrated regulatory network, suggesting that cancer cells exploit metabolic intermediates not solely for energy but as epigenetic modulators to tightly control gene expression in favor of malignancy. Moreover, lactylation emerges as a key epigenetic marker with potential diagnostic and prognostic implications within the prostate cancer continuum.

The clinical implications beckon a new era of metabolic and epigenetic targeted therapy. Given the poor prognosis associated with metastatic prostate cancer, strategies inhibiting RBM14-mediated HK2 mRNA stabilization or disrupting lactate-driven histone modifications could provide transformative benefits. Early-phase clinical trials targeting similar metabolic pathways in other cancers lend credence to the translational feasibility of this approach. Future research might focus on pharmacologic agents specifically designed to modulate lactylation or RBM14 activity, potentially revolutionizing treatment paradigms for metastatic prostate cancer.

Beyond prostate cancer, these findings may have broader impact across oncology, as metabolic-epigenetic cross-talk likely underlies metastatic behaviors in diverse tumor types. RBM14’s role as an RNA-binding protein stabilizer could be a general mechanism leveraged by cancer cells to sustain metabolic adaptations critical for dissemination. The identification of lactylation opens avenues for discovering other lactate-dependent epigenetic marks influencing chromatin state and cancer evolution. This work thus provides a conceptual template for exploring metabolic regulation of chromatin in cancer progression.

Scientifically, the revelation of H3K18 lactylation as a pro-metastatic epigenetic modification invites deeper inquiries into the enzymatic machinery responsible for adding and removing these lactyl groups. Decoding the “writers,” “readers,” and “erasers” of histone lactylation will enrich understanding of how metabolic flux integrates with gene regulation and how such mechanisms are exploited in cancer. Additionally, the crosstalk between lactylation and other histone marks, such as acetylation and methylation, may reveal complex layers of epigenetic control fine-tuning cancer cell identity and plasticity.

On a methodological note, this study exemplifies the power of combining multi-omics approaches, including transcriptomics, metabolomics, and epigenomics, to untangle the multidimensional regulatory networks driving cancer aggressiveness. The sophisticated experimental design involving genetic, biochemical, and pharmacological manipulations allowed for a nuanced dissection of cause-and-effect relationships in the RBM14-HK2-lactylation axis. This comprehensive approach sets a new standard for dissecting molecular pathways underpinning metastasis and highlights the importance of interdisciplinary collaboration.

In sum, Liu, Guo, You, and colleagues’ discovery of RBM14’s role in stabilizing HK2 mRNA to activate glycolysis and induce H3K18 histone lactylation unveils a vital metabolic-epigenetic circuit fueling prostate cancer metastasis. This landmark study not only advances fundamental understanding of cancer biology but also identifies promising therapeutic targets to impede the spread of a devastating disease. As the oncology community seeks innovative strategies to combat metastasis, targeting the metabolic-epigenetic interface illuminated here represents a compelling frontier with enormous translational potential.

The emerging paradigm underscored by this research suggests that future oncologic therapies may need to simultaneously address metabolic vulnerabilities and epigenetic dynamics to effectively halt the complex process of metastasis. By illuminating how RBM14 orchestrates glycolysis and epigenetic remodeling through HK2 mRNA stabilization and H3K18 lactylation, the study paves the way for novel biomarkers and combinatorial treatment strategies aiming at metabolic and epigenetic aberrations. This comprehensive insight fosters hope for markedly improved outcomes for patients suffering from advanced prostate cancer.

In conclusion, this study fundamentally reshapes the understanding of how metabolic reprogramming and histone modifications intersect to drive prostate cancer metastasis. The identification of RBM14 as a critical stabilizer of HK2 mRNA and the elucidation of H3K18 lactylation as a pivotal epigenetic modification open profound new vistas for cancer research and therapeutics. As we advance toward precision medicine, integrating metabolic and epigenetic targeting holds the promise of unlocking more effective therapies to arrest cancer progression and improve patient survival.

Subject of Research: Role of RBM14 in prostate cancer metastasis via HK2 mRNA stabilization and activation of glycolysis and epigenetic modification (H3K18 lactylation).

Article Title: RBM14 drives prostate cancer metastasis via stabilizing HK2 mRNA to activate glycolysis and H3K18 lactylation.

Article References: Liu, Z., Guo, H., You, Z. et al. RBM14 drives prostate cancer metastasis via stabilizing HK2 mRNA to activate glycolysis and H3K18 lactylation. Cell Death Discov. (2026). https://doi.org/10.1038/s41420-026-03131-w

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41420-026-03131-w

At the heart of this fascinating discovery lies eukaryotic translation initiation factor 5A (eIF5A), a protein historically recognized for its unique post-translational modification by hypusine. Hypusination involves the addition of a hypusine residue, derived from the amino acid spermidine, to a specific lysine on eIF5A. This modification is essential for eIF5A’s biological activity and, intriguingly, for its role in facilitating the translation of distinct and often challenging mRNA sequences, such as those with polyproline motifs. Despite its established roles in protein synthesis, the connection between eIF5A hypusination and mitochondrial function had remained elusive—until now.

Mitochondria, known as the cell’s powerhouses, are pivotal in energy production, metabolism, and regulation of apoptosis. Their functionality depends heavily on their own genetic machinery, including mitochondrial tRNAs, which are crucial for the synthesis of proteins encoded by mitochondrial DNA. Proper processing and maturation of mitochondrial tRNA are essential for mitochondrial translation fidelity and efficiency. The study presents compelling evidence that hypusinated eIF5A intricately influences this mitochondrial tRNA processing, a revelation that links cytoplasmic translation regulation with mitochondrial integrity.

Through a combination of biochemical assays, gene editing techniques, and advanced imaging methods, the researchers demonstrated that hypusination of eIF5A modulates the activity of mitochondrial RNase P, an enzyme complex responsible for mitochondrial tRNA processing. In prostate cancer cells exhibiting elevated hypusination levels, enhanced mitochondrial tRNA maturation was observed, which corresponds with increased mitochondrial protein synthesis. This hyperactivation of mitochondrial translation contributes to the metabolic reprogramming often observed in aggressive cancer phenotypes, fostering tumor growth and resistance to apoptosis.

The metabolic shift promoted by hypusinated eIF5A aligns with the concept of metabolic plasticity in cancer cells, where energy production pathways are rewired to support rapid proliferation and survival under hostile conditions. By ensuring proficient mitochondrial tRNA processing, eIF5A hypusination acts as a critical facilitator of this metabolic adaptation. This newly identified axis emphasizes the multifaceted role of translational control in oncogenesis, bridging cytoplasmic and mitochondrial gene expression pathways that were previously considered discrete.

Moreover, the study offers a glimpse into the therapeutic potential of targeting the hypusination pathway. Pharmacologic inhibition of deoxyhypusine synthase (DHS), the enzyme catalyzing the initial step of hypusination, led to diminished mitochondrial tRNA processing efficiency and reduced prostate cancer cell viability in vitro. This suggests that drugs designed to interfere with eIF5A hypusination could selectively impair cancer cell metabolism and growth without broadly affecting normal cells, as hypusination’s role in healthy tissues is more tightly regulated and context-dependent.

Intriguingly, the work also challenges prior assumptions about eIF5A functions being confined predominantly to cytoplasmic translation. By unveiling its impact on mitochondrial RNA processing, the researchers propose a more global role for eIF5A as a molecular integrator of cellular and mitochondrial translational landscapes. This expands the scope of eIF5A’s biological relevance, especially in pathophysiological contexts such as cancer.

Not to be overlooked is the sophisticated methodology employed in this investigation. The team harnessed cutting-edge CRISPR-Cas9 mediated gene editing to generate eIF5A mutants incapable of undergoing hypusination, allowing for precise dissection of functional outcomes. Combined with state-of-the-art mass spectrometry and RNA sequencing, these approaches provided a comprehensive molecular portrait of how hypusination controls mitochondrial gene expression and cellular metabolism in malignant prostate cells.

Another remarkable aspect of the findings relates to the interplay between translational regulation and genomic stability. Dysregulated mitochondrial function is a known contributor to reactive oxygen species (ROS) generation and genomic instability, factors that fuel cancer progression and therapeutic resistance. By maintaining efficient mitochondrial tRNA processing, hypusinated eIF5A may indirectly mitigate these deleterious effects or, conversely, create a metabolic environment conducive to tumor aggressiveness—highlighting the complex balance orchestrated by this modification.

The implications of these discoveries are profound, offering a new perspective on prostate cancer biology that could reshape diagnostic and prognostic strategies. Elevated levels of hypusinated eIF5A or associated mitochondrial processing markers might serve as biomarkers for aggressive disease subtypes, facilitating earlier intervention and more personalized treatment plans. Additionally, this research underscores the broader importance of non-canonical translation factors in cancer biology, urging a reevaluation of other specialized translational modifications in oncogenesis.

From an evolutionary standpoint, the co-option of a cytoplasmic translation factor to regulate mitochondrial tRNA processing highlights the intricate interdependence of cellular compartments. The dual functionality of eIF5A presents a compelling narrative of molecular adaptation, where existing enzymatic machinery is repurposed to meet the heightened metabolic demands of proliferating cancer cells. This phenomenon exemplifies the dynamic plasticity of cellular regulatory networks in health and disease.

Further exploration is warranted to unravel whether similar mechanisms of hypusination-mediated mitochondrial regulation operate across other cancer types or in diverse pathological conditions characterized by mitochondrial dysfunction. Such studies could open new frontiers in understanding how translational control intersects with organelle biology and systemic metabolism.

The study also prompts intriguing questions about the regulation of hypusination itself. Since this modification relies on the availability of spermidine, a polyamine whose metabolism is frequently altered in cancer, understanding the upstream regulatory pathways controlling spermidine levels might provide additional therapeutic targets or modulation strategies to influence eIF5A activity indirectly.

In conclusion, this landmark work brings hypusination of eIF5A into the spotlight as a crucial regulator of mitochondrial tRNA processing with direct implications for prostate cancer aggressiveness. The integration of translation control and mitochondrial function elucidated here offers promising new insights into tumor metabolism and highlights novel molecular targets for combating aggressive prostate cancer. As efforts accelerate to translate these findings into clinical applications, the hope is to harness this knowledge to improve outcomes for patients facing this formidable disease.

Subject of Research: The regulation of mitochondrial tRNA processing by hypusination of the translation factor eIF5A and its role in promoting prostate cancer aggressiveness.

Article Title: Hypusination of the translation factor eIF5A regulates mitochondrial tRNA processing to promote prostate cancer aggressiveness.

Article References:
Kahi, M., Mazzu′, A., Batistic, L. et al. Hypusination of the translation factor eIF5A regulates mitochondrial tRNA processing to promote prostate cancer aggressiveness. Nat Commun (2026). https://doi.org/10.1038/s41467-026-70566-1

Image Credits: AI Generated